- Home
- PTGX vs ACLX Comparison
PTGX vs ACLX Comparison
Compare PTGX & ACLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
Current Price
$89.29
HOLD
Current Price
$68.70
Company Overview
Basic Information| Metric | PTGX | ACLX |
|---|---|---|
| Founded | 2006 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.4B | 4.2B |
| IPO Year | 2016 | 2022 |
Fundamental Metrics
Financial Performance| Metric | PTGX | ACLX |
|---|---|---|
| Price | $89.29 | $68.70 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 9 |
| Target Price | $86.44 | ★ $115.50 |
| AVG Volume (30 Days) | 898.7K | ★ 1.2M |
| Earning Date | 11-06-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.72 | N/A |
| Revenue | ★ $209,217,000.00 | $35,898,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $296.47 | $302.49 |
| P/E Ratio | $124.48 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $33.70 | $47.86 |
| 52 Week High | $93.25 | $94.07 |
Technical Indicators
Market Signals| Indicator | PTGX | ACLX |
|---|---|---|
| Relative Strength Index (RSI) | 64.67 | 33.01 |
| Support Level | $83.52 | $66.00 |
| Resistance Level | $90.85 | $75.03 |
| Average True Range (ATR) | 2.63 | 5.23 |
| MACD | -0.33 | -1.69 |
| Stochastic Oscillator | 83.62 | 12.96 |
Price Performance
Historical Comparison PTGX
ACLX
About PTGX Protagonist Therapeutics Inc.
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.
About ACLX Arcellx Inc.
Arcellx Inc a clinical-stage biotechnology company reimagining cell therapy through the development of immunotherapies for patients with cancer and other incurable diseases. Its pipeline includes Multiple Myeloma, Acute Myeloid Leukemia, Non-Oncology, and Solid Tumors.